Table 2.

Multivariate analysis of urine EV biomarkers and SOC variables for any cancer and high-grade PCa in the validation cohort.

Predictor	Cancer vs. No Cancer OR (95% CI); p-value	Gleason Score ≥7 vs <7 OR (95% CI); p-value
log_PCA3	1.96 (0.95 to 4.05); 0.069	1.63 (0.91 to 2.90); 0.099
log_GATA2	1.80 (1.07 to 3.03); 0.027	2.15 (1.31 to 3.53); 0.002
TE
TE>0	2.62 (1.09 to 6.26); 0.031	2.70 (1.23 to 5.92); 0.013
PSA	0.97 (0.92 to 1.04); 0.414	0.97 (0.91 to 1.03); 0.340
Age	0.98 (0.92 to 1.04); 0.456	0.98 (0.93 to 1.03); 0.469
Race
African-American	3.39 (0.19 to 83.98); 0.552	12.88 (0.49 to 294.24); 0.316
Other	2.19 (0.21 to 23.18); 0.950	5.40 (0.49 to 59.38); 0.780
Family History of PCa
Yes	0.49 (0.15 to 1.59); 0.236	0.41 (0.13 to 1.27); 0.123

EV=extracellular vesicles; SOC=standard of care; PCa=prostate cancer; TE=TMPRSS2-ERG; OR=odds ratio; CI=confidence interval